Skip to main content

Hahn Signals COVID-19 Could Affect User Fee Goals, Device Talks Put Off

An article published by Inside Health Policy quoted remarks made by Senior Director of ML Strategies Aaron Josephson during a recent Mintz and ML Strategies webinar focused on the U.S. Food and Drug Administration (FDA)’s response to the COVID-19 pandemic.

Mr. Josephson’s comments were in reference to FDA Commissioner Stephen Hahn’s statement that the agency continues to meet its user fee commitments and the agency’s indefinite postponement of its initial medical device user fee meeting for the upcoming reauthorization cycle.


Inside Health Policy